The Latest

Dr. Matias Fernandez Viña, M.D, cPhD, counts among his titles: Assistant Professor of Universidad Abierta Interamericana of Medicine, Latin American Section Chief of American College of Regenerative Medicine, and Medical Director of REGENERÓN, among others. He is therefore both an expert and perpetual student of Regenerative Medicine and has recently turned his attention to the generation and interpretation of real-world data through RegenMed's Circles.Dr. Viña first selected a pathology (Knee OA) and patient-reported outcomes measure (KOOS + VAS) to begin gathering outcomes data from his patients. Second, he devised a clinically efficient, "real world" protocol to help correlate clinical factors to patient outcomes. Currently, his interest is in comparing two common treatment options, PRP and processed adipose, and using his custom-designed protocols to inform considerations on efficacy, safety, and costs of these novel treatments.If you would like to learn more about Dr. Viña's real-world data study, early results, or explore opportunities for collaboration, reach out today.

We are proud to present the first CELLS Webinar, featuring Drs. Jose Miguel Catalán and Severiano Dos Anjos Vilaboa, as they describe their objectives, methods, and results in intraosseous PRP injection for knee OA. The short, pre-recorded video is available to stream for free by clicking on the image thumbnail, or the "Watch Full Episode Button". We hope you find it informative for your practice, and look forward to presenting subsequent episodes later this year.Episode Includes:Dr. Catalán’s Regenerative Medicine PracticeKnee OA Structural and Biological ChallengesIntraosseous Treatment Protocol for Knee OAChallenges in Variability and Clinical Performance: PRP and BMACStudy Methods and ProtocolPatient Results, Cohorts, and Early CorrelationsInterested in more information or getting more involved? Please state your interest through our Contact page, and a RegenMed representative will be in touch shortly.

Dr. Jaspal Singh, Vice-Chair and Associate Professor of Weill Cornell’s Department of Rehabilitation Medicine, specializes in providing comprehensive, personalized treatment plans. This, coupled with a growing patient interest, has inspired him to add regenerative medicine expertise to his clinical armamentarium. Working with RegenMed, and pictured here with Nicolas Tierney, COO, Dr. Singh is developing a series of Circles that support evidence-based clinical decision making in this new field. Components of his Circles will include:Institutional IRB approval with a focus on common MSK indications.Remote patient monitoring, outcomes capture, and benchmarking for up to two years post-treatmentCharacterization and correlation of specific markers within Human/Cell Tissue Products “HCT/P” assays.A regular webinar series, sharing his real-world data results and recommendations with colleagues.An open invitation to other “Good Actors” who wish to aggregate and interpret similar real-world data. To learn more about Dr. Singh’s procedures, Circles, or upcoming webinar series, please contact us.

CELLS, or the “Clinical Evidence Leadership Lecture Series”, is back in a new digital format. Featuring clinician leaders from around the world, these concise, evidence-packed series will be made available immediately upon release to all RegenMed subscribers. There are no fees, scheduling hassles, or viewer requirements, just clinically relevant content.The first series, titled PRP & BMAC, will cover protocols, corresponding real-world data, and insightful commentary from "good actor" clinicians and scientists regarding this increasingly important regenerative medicine approaches, whether uses as primary or adjunct therapies. Episode 1: “Intraosseous PRP for Knee OA” will feature Jose Miguel Catalán, M.D. of Palma Mallorca, Spain, and his scientific collaborator, Severiano Dos Anjos, Ph.D. as they cover:The Knee OA pathology at a biological level.Typical challenges with orthobiologic treatments, including intraarticular approaches and PRP variability.Details on Dr. Catalán’s intraosseous technique and approach.Relevant data points and uses for PRP characterization data.A real-world evidence protocol that correlates Dr. Catalan’s early real-world data against long-term patient outcomes.Opportunities for viewers to collaborate in the delivery, assessment, and standardization of this technique with their own patient population.We hope you enjoy the trailer and will update all RegenMed newsletter subscribers when the full episode is available for streaming.For more information on this episode, Dr. Catalán’s Circle, or participating in a future CELLS video, please contact ntierney@rgnmed.com.

Poor patient engagement can lead to non-compliance, adverse outcomes and substantial expense. (Lack of medicinal adherence costs the US healthcare system over $250 billion per year.) Those same issues affect research, whereby patients are too unmotivated, over-burdened, or both, to report upon their long term progress. And yet obtaining these results consistently and across a heterogenous population of patients is key to the success of generating real world evidence, which is increasingly used by manufacturers, institutions and private clinics to support safety and efficacy of their products and protocols.The stationary bicycle company Peloton has become a health and wellness success story based on engaging its customer base. It boasts over 4.4 million members on its digital platform, but even more interestingly, has doubled its per subscriber monthly workout totals over the last year. How does Peloton get its members off couches and onto bikes? By fostering among them an ongoing sense of competition.Member data, such as kilojoules of generated energy, is consistently tracked by the Peloton platform and presented back to the user. A Peloton “Member” thus regularly and easily quantifies her progress, compares it against pre-established goals as well as against others in the Peloton database. The engagement and results of this “gamification” speak for themselves.Clinicians, researchers and product manufacturers can apply these lessons to their own patient engagement initiatives, by:Choosing simple, effective “patient-accessible” quantification metrics. PROMs are good; surveys based on objective, sensor-based data are better.Weighing benefits against burdens from the patient’s perspective. Consider the length and complexity of the survey related to the perceived value of its metric.Providing immediate, quantitative feedback upon patient completion. Provide context, provide goals and if relevant, even comparison “competition” against others within their cohort.These and similar elements will greatly improve patient engagement, and are at the heart of any Circle we manage.